Question 1

Can I switch from Trulicity to Wegovy if I have T2D and obesity?

Accepted Answer

Yes, and it is a common transition when weight loss becomes the primary goal. Trulicity (dulaglutide) is FDA-labeled only for type 2 diabetes; Wegovy (semaglutide 2.4 mg) is labeled for chronic weight management and will continue to lower A1C as a class effect even though that is off-label. Standard practice is to discontinue Trulicity and restart at Wegovy 0.25 mg the following week, then titrate over 16 weeks to 2.4 mg. Expect a brief GI-tolerability period during re-titration.

Question 2

Will my insurance approve Wegovy if Trulicity worked but I want more weight loss?

Accepted Answer

Often not without friction. Most commercial plans separate diabetes and obesity benefits — Trulicity sits in the T2D bucket and Wegovy in obesity, which many plans exclude entirely or require BMI ≥30 (or ≥27 with comorbidity) plus documented lifestyle intervention. If your plan covers obesity medications, prior auth typically requires 12+ weeks at maximum tolerated Trulicity dose with inadequate weight response. If the obesity benefit is excluded, NovoCare direct-pay at $349-$499/month is often cheaper than retail.

Question 3

Is Wegovy or Trulicity better for a diabetic patient trying to lose weight?

Accepted Answer

Wegovy, by a wide margin on weight outcomes. STEP-1 (Wilding 2021 NEJM, PMID 33567185) showed semaglutide 2.4 mg produced -14.9% body weight at 68 weeks in adults with obesity. Trulicity's weight-loss effect in T2D trials runs roughly 2-3 kg even at the 4.5 mg dose — meaningfully less. SUSTAIN-7 (Pratley 2018 Lancet Diabetes Endocrinol, PMID 29397376) compared the molecules head-to-head in T2D and showed semaglutide 1 mg beat dulaglutide 1.5 mg on both A1C (-1.8% vs -1.4%) and weight. The dose-doubling in Wegovy amplifies that gap further.

Question 4

What happens to my A1C if I switch from Trulicity to Wegovy?

Accepted Answer

It typically improves or stays stable. Even though Wegovy is labeled for obesity, not diabetes, semaglutide 2.4 mg lowered A1C ~1.5% in the STEP 2 trial of T2D patients with obesity. SUSTAIN-7 head-to-head showed semaglutide 1 mg dropping A1C 1.8% vs dulaglutide 1.5 mg's 1.4% — and Wegovy's higher 2.4 mg dose pushes that effect further. Most patients see equivalent or improved glycemic control. Monitor for hypoglycemia if you also take sulfonylureas or insulin; dose reductions may be needed during titration.

Question 5

Can my child switch from Trulicity to Wegovy?

Accepted Answer

Age matters. Trulicity is FDA-approved for type 2 diabetes from age 10 (based on the AWARD-PEDS pediatric trial). Wegovy is FDA-approved for chronic weight management from age 12 (based on STEP TEENS). A child aged 10-11 on Trulicity for T2D cannot switch to on-label Wegovy until age 12. From 12 onward, the switch is feasible if obesity meets BMI criteria (≥95th percentile for age). Coordinate with a pediatric endocrinologist — pediatric prior auth is stricter than adult.

Question 6

Does Trulicity have any advantage over Wegovy?

Accepted Answer

Three meaningful ones. First, cardiovascular outcomes in type 2 diabetes — REWIND (Gerstein 2019 Lancet, PMID 31189511) randomized 9,901 T2D patients (69% without prior CV disease) and showed Trulicity cut MACE 12% over 5.4 years, the broadest primary-prevention CV evidence among GLP-1s. Second, pediatric coverage starts at age 10 vs Wegovy's 12. Third, the Lilly savings card brings copays to ~$25/month for commercially insured T2D patients, which can undercut Wegovy's $349-$499 NovoCare direct-pay tier.

Field	Trulicity	Wegovy
FDA-approved indication	Type 2 diabetes (adults + pediatric ≥10); CV risk reduction in T2D	Chronic weight management (adults + pediatric ≥12); CV risk reduction in obesity
Weight loss (pivotal data)	~2-3 kg at 26-52 wk (T2D trials, 1.5-4.5 mg)	-14.9% body weight at 68 wk (STEP-1, 2.4 mg)
A1C reduction (head-to-head proxy: SUSTAIN-7)	-1.4% (dulaglutide 1.5 mg / 40 wk)	-1.8% (semaglutide 1.0 mg / 40 wk — same molecule as Wegovy)
Cardiovascular outcome	MACE -12% in T2D (REWIND, 9,901 pts, primary + secondary prevention)	MACE -20% in obesity without diabetes (SELECT, 17,604 pts)
Dosing	Once-weekly subq 0.75 / 1.5 / 3.0 / 4.5 mg (auto-injector)	Once-weekly subq 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg (5-step titration)
Cash price (manufacturer)	~$987/mo retail; Lilly savings card to $25/mo for commercially insured T2D patients	$349/mo first 2 months, then $499/mo via NovoCare direct-pay
Pediatric indication	Approved for T2D from age 10 (AWARD-PEDS trial)	Approved for chronic weight management from age 12 (STEP TEENS)
Switching logistics	Discontinue prior week; no washout typically needed	Start at 0.25 mg regardless of prior GLP-1; 16-week titration to 2.4 mg

Trulicity vs Wegovy (2026): T2D Switch for Weight Loss, Cost, CV

The verdict

Side-by-side comparison

Frequently asked questions